ONCOLOGY, NUCLEAR MEDICINE AND TRANSPLANTOLOGY
Review Article
Oct 08, 2025 9 4

The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer

Tosin Ayodeji Oladosu 1 * ,
Chinaecherem Peace Okafor 2,
Patrick Chinazam Nwosu 3,
Ayo Ebunolorun Ibukunoluwa 4,
Uduh Ifeoma Monica 5,
Tosin Abiodun Aderanti 6
1 Department of Chemistry and Biochemistry, University of Minnesota Duluth, Duluth, MN, USA2 Department of Biochemistry, Federal university of Technology, Owerre, Imo State, Nigeria3 Clinical Lead Rehabilitation and Quality Department, San Ramo Nursing and Rehabilitation Center, Garland, TX, USA4 Department of Nutritional Sciences, Auburn University, Auburn, AL, USA5 Department of Dentistry, University of Port Harcourt, Port Harcourt, Rivers State, Nigeria 6 Department of Chemical and Environmental Sciences, Babcock University, Ilishan-Remo, Ogun State, Nigeria* Corresponding Author
Oncology, Nuclear Medicine and Transplantology, 1(1), 2025, onmt006, https://doi.org/10.63946/onmt/17244
Publication date: Oct 08, 2025
Full Text (PDF)

ABSTRACT

Liquid biopsies have developed as a revolutionary technique in cancer diagnosis, treatment evaluation, and the detection of therapeutic resistance. Unlike traditional tissue biopsies, which are invasive and limited to a single temporal analysis, liquid biopsies offer a non-invasive, real-time evaluation of tumour dynamics through the analysis of biomarkers such as circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), exosomes, and microRNAs. This approach enables continuous monitoring of tumour advancement, allowing for the early detection of cancer, the tracking of minimal residual disease, and the identification of emerging resistance mutations. As cancers advance and acquire resistance to therapies, liquid biopsy provides critical information that enables clinicians to customise treatment strategies and improve outcomes. Despite challenges such as sensitivity limitations in early-stage cancers and the necessity for standardised testing protocols, technological advancements, including next-generation sequencing (NGS), CRISPR, and AI-driven analytics, are enhancing the precision and accessibility of liquid biopsies. Through ongoing validation and cost-reduction efforts, liquid biopsies are set to become essential to precision oncology, offering a transformative approach to cancer therapy that could improve patient outcomes and foster equitable healthcare globally.

KEYWORDS

Liquid Biopsy Circulating Tumor DNA (ctDNA) Therapeutic Resistance Minimal Residual Disease (MRD) Precision Oncology

CITATION (Vancouver)

Oladosu TA, Okafor CP, Nwosu PC, Ibukunoluwa AE, Monica UI, Aderanti TA. The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer. Oncology, Nuclear Medicine and Transplantology. 2025;1(1):onmt006. https://doi.org/10.63946/onmt/17244
APA
Oladosu, T. A., Okafor, C. P., Nwosu, P. C., Ibukunoluwa, A. E., Monica, U. I., & Aderanti, T. A. (2025). The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer. Oncology, Nuclear Medicine and Transplantology, 1(1), onmt006. https://doi.org/10.63946/onmt/17244
Harvard
Oladosu, T. A., Okafor, C. P., Nwosu, P. C., Ibukunoluwa, A. E., Monica, U. I., and Aderanti, T. A. (2025). The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer. Oncology, Nuclear Medicine and Transplantology, 1(1), onmt006. https://doi.org/10.63946/onmt/17244
AMA
Oladosu TA, Okafor CP, Nwosu PC, Ibukunoluwa AE, Monica UI, Aderanti TA. The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer. Oncology, Nuclear Medicine and Transplantology. 2025;1(1), onmt006. https://doi.org/10.63946/onmt/17244
Chicago
Oladosu, Tosin Ayodeji, Chinaecherem Peace Okafor, Patrick Chinazam Nwosu, Ayo Ebunolorun Ibukunoluwa, Uduh Ifeoma Monica, and Tosin Abiodun Aderanti. "The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer". Oncology, Nuclear Medicine and Transplantology 2025 1 no. 1 (2025): onmt006. https://doi.org/10.63946/onmt/17244
MLA
Oladosu, Tosin Ayodeji et al. "The Role of Liquid Biopsies in Tracking Tumor Evolution and Overcoming Therapeutic Resistance in Cancer". Oncology, Nuclear Medicine and Transplantology, vol. 1, no. 1, 2025, onmt006. https://doi.org/10.63946/onmt/17244

REFERENCES

  1. Adhit KK, Wanjari A, Menon S, K S. Liquid Biopsy: An Evolving Paradigm for Non-invasive Disease Diagnosis and Monitoring in Medicine. Cureus. 2023 Dec 8;15(12):e50176. doi:10.7759/cureus.50176
  2. Baldassarre G, Serna IL de la, Vallette FM. Death-ision: the link between cellular resilience and cancer resistance to treatments. Molecular Cancer. 2025 May 15;24:144. doi:10.1186/s12943-025-02151-7
  3. Hirahata T, Quraish R ul, Quraish A ul, Quraish S ul, Naz M, Razzaq MA. Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer. Cancer Informatics. 2022 Feb 7;21:11769351221076062. doi:10.1177/11769351221076062
  4. Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct Target Ther. 2024 Dec 2;9:336. doi:10.1038/s41392-024-02010-1
  5. Zhang Y, Wang W. Advances in tumor subclone formation and mechanisms of growth and invasion. J Transl Med. 2025 Apr 21;23:461. doi:10.1186/s12967-025-05879-0
  6. Yin H, Zhang M, Zhang Y, Zhang X, Zhang X, Zhang B. Liquid biopsies in cancer. Mol Biomed. 2025 Mar 20;6:18. doi:10.1186/s43556-025-00166-8
  7. Lawrence R, Watters M, Davies CR, Pantel K, Lu YJ. Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol. 2023 Jun 2;1–14. doi:10.1038/s41571-023-00781-y
  8. Labib M, Kelley SO. Circulating tumor cell profiling for precision oncology. Mol Oncol. 2021 Jun;15(6):1622–46. doi:10.1002/1878-0261.12988
  9. Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. eBioMedicine. 2022 Aug 27;83:104237. doi:10.1016/j.ebiom.2022.104237
  10. Javdani-Mallak A, Mowla SJ, Alibolandi M. Tumor-derived exosomes and their application in cancer treatment. J Transl Med. 2025 Jul 8;23:751. doi:10.1186/s12967-025-06051-4
  11. Sychowski G, Romanowicz H, Ciesielski W, Hogendorf P, Durczyński A, Smolarz B. Diagnostic and Therapeutic Potential of Selected microRNAs in Colorectal Cancer: A Literature Review. Cancers. 2025 Jan;17(13):2135. doi:10.3390/cancers17132135
  12. Saha D, Kanjilal P, Kaur M, Menon SV, Ashraf A, Kumar MR, et al. Transforming Cancer Diagnostics: The Emergence of Liquid Biopsy and Epigenetic Markers. MedComm (2020). 2025 Sep 14;6(9):e70388. doi:10.1002/mco2.70388
  13. Pandey S, Yadav P. Liquid biopsy in cancer management: Integrating diagnostics and clinical applications. Pract Lab Med. 2024 Dec 24;43:e00446. doi:10.1016/j.plabm.2024.e00446
  14. Wu HJ, Chu PY. Current and Developing Liquid Biopsy Techniques for Breast Cancer. Cancers. 2022 Jan;14(9):2052. doi:10.3390/cancers14092052
  15. El Nachef L, Bouchet A, Bourguignon M, Foray N. When DNA Mutations Interplay with Cellular Proliferation: A Narrative History of Theories of Carcinogenesis. Cancers. 2024 Jan;16(11):2104. doi:10.3390/cancers16112104
  16. Wang H, Zhang Y, Zhang H, Cao H, Mao J, Chen X, et al. Liquid biopsy for human cancer: cancer screening, monitoring, and treatment. MedComm (2020). 2024 May 28;5(6):e564. doi:10.1002/mco2.564
  17. Asadi M, Zafari V, Sadeghi-Mohammadi S, Shanehbandi D, Mert U, Soleimani Z, et al. The role of tumor microenvironment and self-organization in cancer progression: Key insights for therapeutic development. Bioimpacts. 2024 Dec 7;15:30713. doi:10.34172/bi.2024.30713
  18. Fatima S. Tumor Microenvironment: A Complex Landscape of Cancer Development and Drug Resistance. Cureus. 2025;17(4):e82090. doi:10.7759/cureus.82090
  19. Lei Z, Tian Q, Teng Q, Wurpel JND, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm (2020). 2023 May 22;4(3):e265. doi:10.1002/mco2.265
  20. Liu J, Cai Y, Liu J, Chen D, Wu X. Immunotherapy Resistance and Therapeutic Strategies in PD-L1 High Expression Non-Small Cell Lung Cancer. Onco Targets Ther. 2025 Aug 29;18:953–66. doi:10.2147/OTT.S503348
  21. Wu J, Lin Z. Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance. International Journal of Molecular Sciences. 2022 Jan;23(23):15056. doi:10.3390/ijms232315056
  22. Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, et al. Liquid biopsies: the future of cancer early detection. J Transl Med. 2023 Feb 11;21:118. doi:10.1186/s12967-023-03960-8
  23. Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Sig Transduct Target Ther. 2024 Dec 2;9(1):336. doi:10.1038/s41392-024-02010-1
  24. Bartolomucci A, Nobrega M, Ferrier T, Dickinson K, Kaorey N, Nadeau A, et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol. 2025 Mar 24;9:84. doi:10.1038/s41698-025-00663-3
  25. Song M, Pan W, Yu X, Ren J, Tang C, Chen Z, et al. Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment. MedComm (2020). 2025 May 15;6(6):e70193. doi:10.1002/mco2.70193
  26. Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Sig Transduct Target Ther. 2024 Dec 2;9(1):336. doi:10.1038/s41392-024-02010-1
  27. Qureshi Z, Altaf F, Khanzada M, Safi A, Asghar Z, Warraich D, et al. Liquid biopsies for early detection and monitoring of cancer: advances, challenges, and future directions. Ann Med Surg (Lond). 2025 May 21;87(6):3244–53. doi:10.1097/MS9.0000000000002859
  28. Lin C, Liu X, Zheng B, Ke R, Tzeng CM. Liquid Biopsy, ctDNA Diagnosis through NGS. Life (Basel). 2021 Aug 28;11(9):890. doi:10.3390/life11090890
  29. Neagu AN, Bruno PS, Josan CL, Waterman N, Morrissiey H, Njoku VT, et al. In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy. Proteomes. 2025 Dec;13(4):47. doi:10.3390/proteomes13040047
  30. Shegekar T, Vodithala S, Juganavar A. The Emerging Role of Liquid Biopsies in Revolutionising Cancer Diagnosis and Therapy. Cureus. 2023;15(8):e43650. doi:10.7759/cureus.43650

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.